Trade name
Azzalure, 10 Speywood units/0.05 ml, powder for solution for injection
Company
Q-Med, a Galderma Division
Description
Botulinum toxin type Aa 10 Speywood units b/0.05 ml of reconstituted solution
Vial of 125 units
The Speywood units of Azzalure are specific to the preparation and are not interchangeable with other preparations of botulinum toxin
Pharmaceutical Form:
Powder for solution for injection
The powder is white
Posology:
The recommended dose is 50 Speywood units (0.25 ml of reconstituted solution) of Azzalure to be divided into 5 injection sites, 10 Speywood units (0.05 ml of reconstituted solution) are to be administered intramuscularly into each of the 5 sites: 2 injections into each corrugator muscle and one into the procerus muscle
During the clinical development of Azzalure, more than 2,600 patients were included in the different clinical trials
In clinical studies, 1,907 patients with moderate to severe glabellar lines have been treated at the recommended dose of 50 Speywood units. Of these, 305 were treated with 50U in two pivotal phase III double-blind placebo-controlled studies and 1,200 treated with 50U in a long-term open-label repeated-dose phase III study. The remaining patients were treated in supportive and dose-ranging studies [1–6]
Intended use
Azzalure is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) seen at frown, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient
Onset of response and duration
The median time to onset of response was 2–3 days following treatment, with the maximum effect observed at day 30. In two pivotal placebo-controlled phase III studies, Azzalure injections significantly reduced the severity of glabellar lines for up to 4 months. The effect was still significant after 5 months in one of the two pivotal studies. Treatment interval should not be more frequent than every three months
Azzalure: Reference
1.
Ascher B, Zakine B, Kestemont P et al. (2004) A multicentre, randomized, double-blind, placebo-controlled study of efficacy and safety of three doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad of Dermatol 51(2):223–33
2.
Ascher B, Zakine B, Kestemont P et al. (2005) Botulinum tox A in the treatment of glabellar lines: scheduling the next injection. Aesth Surg J 25:365–375
3.
Monheit G, Carruthers A, Brandt F, Rand R (2007) A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 33(1):S51–S59
4.
Moy R, Maas C, Monheit G, Huber B (2009) Long-term safety and efficacy of a new botulinum toxin type A in treatment glabellar lines. Arch Facial Plast Surg 11(2):77–83
5.
Rzany B, Dill-Mueller D, Grablowitz D et al. (2007) Repeated botulinum toxin A injections for the treatment lines in the upper face: a retrospective study of 103 treatments in 945 patients. Dermatol Surg 33:S18–S25
6.
Rzany B, Asher B, Monheit GD (2010) Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a Clinical overview. JEADV 24(1):1–14
24.2 Belotero Range
24.2.1 Belotero Basic Filler
Trade name | Belotero basic |
|---|---|
Volume/package | Cross-linked sodium hyaluronate: 22.5 mg/ml in 1-ml glass syringe |
Company | Merz Pharma |
Certifications | CE, FDA |
Commercialization | 2006 |
Austria, Germany, Italy, Russia, Switzerland, UK and USA | |
Description | Belotero Basic is a sterile, pyrogenic, viscoelastic clear colourless transparent, isotonic gel. Belotero Basic consists of cross-linked sodium hyaluronate of non-animal origin Belotero has a CPM® technology based on a dynamic, double cross-linking process of the cohesive monophasic hyaluronic acid gel with the stabilizer BDDE1 |
The unique Cohesive Polydensified Matrix (CPM®) provides a stable, cohesive gel and provides outstanding product qualities as low-viscosity properties that make it able to fill in even the tightest intradermal spaces, homogenous distribution into the dermis, smooth transitions between treated and untreated areas and low injection pressure making treatment nearly pain-free | |
Intended use | Belotero Basic is an injectable implant indicated for use to increase the volume of skin tissue which enables: the correction of facial depressions, either due to injury or age-related (scarring, moderate or deep wrinkles, furrows), remodelling of the contours of the face by injection into facial areas such as the cheeks, chin, etc., increase in lip volume (the border of the red part of the lip, increasing roundness) |
Duration | No published data |
Needle TWN | 2 27 G½ (0.4 × 1.3 mm) (supplied) |
Suggested cannulas | 30 G 1 inch; 27 G 1½ inch; 25 G 1½ inch; 25 G 2 inch (not supplied) |
24.2.2 Belotero Soft Filler
Trade name | Belotero soft |
|---|---|
Company | Merz Pharma |
Volume/Package | Cross-linked sodium hyaluronate: 20 mg/ml in 1-ml glass syringe |
Certifications | CE, FDA |
First commercialization | 2006 |
Austria, Germany, Italy, Russia, Switzerland and UK | |
Description | Belotero soft is a sterile, pyrogenic, viscoelastic clear colourless transparent, isotonic gel. Belotero Basic consists of cross-linked sodium hyaluronate of non-animal origin Belotero has a CPM® technology based on a dynamic, double cross-linking process of the cohesive monophasic hyaluronic acid gel with the stabilizer BDDE1 |
The unique Cohesive Polydensified Matrix (CPM®) provides a stable, cohesive gel and provides outstanding product qualities as low-viscosity properties that make it able to fill in even the tightest intradermal spaces, homogenous distribution into the dermis, smooth transitions between treated and untreated areas and low injection pressure making treatment nearly pain-free | |
Intended use | Belotero Soft is an injectable implant indicated for use to increase the volume of skin tissue which enables: to correct shallow facial depressions, either due to injury or age-related (scars, fine lines, crow’s feet wrinkles), to retouch a correction undertaken with Belotero Basic, immediately or a few weeks after the first injection |
Duration | No published data |
Needle TWN | 2 30 G1″/2 (0.3 × 13 mm) (supplied) |
Suggested cannulas | 30 G 1 inch; 27 G 1½ inch (not supplied) |
24.2.3 Belotero Intense Filler
Trade name | Belotero intense |
|---|---|
Company | Merz Pharma |
Volume/Package | Cross-linked sodium hyaluronate: 25.5 mg/ml in 1-ml glass syringe |
Certifications | CE, FDA |
First commercialization | 2009 |
Austria, Germany, Italy, Russia, Switzerland, UK and USA | |
Description | Belotero soft is a sterile, pyrogenic, viscoelastic clear colourless transparent, isotonic gel. Belotero Basic consists of cross-linked sodium hyaluronate of non-animal origin Belotero has a CPM® technology based on a dynamic, double cross-linking process of the cohesive monophasic hyaluronic acid gel with the stabilizer BDDE1 |
The unique Cohesive Polydensified Matrix (CPM®) provides a stable, cohesive gel and provides outstanding product qualities as low-viscosity properties that make it able to fill in even the tightest intradermal spaces, homogenous distribution into the dermis, smooth transitions between treated and untreated areas and low injection pressure making treatment nearly pain-free | |
Intended use | Belotero Intense is an injectable implant indicated to restore or significantly improve deep folds and augment face skin volume defects which enables: the correction of facial depressions, either due to injury or age-related (scarring, deep wrinkles, furrows), remodelling of the contours of the face by injection into facial areas such as the cheeks, chin, etc., lip enhancement especially the border of the red part of the lip |
Duration | No published data |
Needle TWN | 2 21 Gy 2 (0.4 × 13 mm) needles (supplied) |
Suggested cannulas | 27 G 1½ inch; 25 G 2 inch (not supplied) |
Belotero: Reference
1.
Huber J. Efficacy of combined treatment using hyaluronic acid (belotero® soft) and botulinium toxin type A (xeomin®) to optimize aesthetic outcome in radial upperlid lines. Kosmetische Medizin 3(10):4–10
2.
Pavicic T, Ruzicka T, Korting H–K, Gauglitz G. Monophasic (2010) Cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients. J Drugs Dermatol 9(6): 690–695
3.
Prager W, Steinkraus V (2010) A prospective, rater-blind, randomized comparison of the effectiveness and tolerability of belotero® basic versus restylane® for correction of nasolabial folds. Eur J Dermatol
4.
Reinmüller J, Wolters M, Lampe H, Steinkraus V, Dirting K, Sommer B, Leva S, Flatau-Baque B (2007)Poster presented at the 21st World Congress of Dermatology, Buenos Aires, Argentina, Sept 30–Oct 5 2007. (This was then published as a supplement to Dermatology News: Kammerer S (2007) Belotero®: a CPM®-technology based HA-filler. easy handling, smooth spreading in the tissues. Dermatol News 2007(11):2–3)
5.
Taufig AZ, Szöke A, Kühnel W (2009) A new strategy to detect intradermal reactions after injection of resorbable dermal fillers. J Ästhetische Chirurgie 2:29–36
24.3 Bocouture
24.3.1 Botulinum Toxin Merz-A Drug
Trade name | Bocouture, Xeomin, Xeomin cosmetic and Xeomeen |
|---|---|
Company | Merz Pharma |
Volume/Package | 1 vial containing 50 LD50 units of Botulinum toxin type A 0.1 ml solution contains 4 LD50 units of Botulinum toxin type A (150 kD) reconstituted in 1.25 ml |
Certifications | FDA |
First commercialization | 2011 |
Argentina (Xeomin), Austria (Bocouture), Belgium (Bocouture), France (Bocouture), Germany (Bocouture), Italy (Bocouture), Mexico (Xeomeen), Netherlands (Bocouture), Portugal (Bocouture), Russia (Xeomin), Spain (Bocouture), Sweden (Bocouture), UK (Bocouture) and USA (Xeomin) | |
Description | Bocouture® Botulinum Toxin Type A is a highly pure neuromodulator formulation that contains only active neurotoxin and that is free from complexing proteins; thanks to a precision engineering process, Bocouture contains pure (150 kD) neurotoxin. Due to its purity, Bocouture® could be beneficial in reducing the risk of non-response or a decrease in response, especially in long-term treatment |
Bocouture® is highly stable and the only botulinum toxin type A that does not have to be refrigerated during transportation or storage Complete recovery of endplate function/impulse transmission after injection normally occurs within 3–4 months as nerve terminals sprout and reconnect with the endplate | |
Intended use | Bocouture is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at frown (glabellar frown lines) in adults below 65 years when the severity of these lines has an important psychological impact for the patient |
Duration | An improvement in the glabellar frown lines generally takes place within 2–3 days with the maximum effect observed on day 30. The effect lasts up to 4 months after the injection. The intervals between treatments should not be shorter than 3 months |
Needle TWN | Reconstituted Bocouture is injected using a thin sterile needle (e.g. 30-gauge needle) (not supplied) |
Suggested cannulas |
Bocouture Botulinum Toxin-A Drug: Reference
1.
Bocouture SmPC June 2010
2.
Frevert J (2010) Drugs in R&D 10(2):1–7
3.
Grein S et al. Mov Discord 23; Supplement 1, S24 (2008) Xeomin is stable without refrigeration. Complexing proteins are not required for stability of Botulinum neurotoxin type A preparations
24.4 Emervel Range
Trade name | Emervel touch |
|---|---|
Company | Q-Med, a Galderma Division |
Volume/Package | 1 ml |
Certifications | CE-2010 |
First commercialization | 2011 |
Description | Emervel® Touch is a viscoelastic, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction |
Intended use | Emerve® Touch is an injectable dermal filler used to augment the volume of facial tissues. Emervel® Touch is indicated for injection into the superficial dermis for the correction of superficial wrinkles |
Duration | Emervel® Touch increases the volume of the dermis for a period of 6–9 months |
Needle UTW | 30 G½ (supplied) |
Trade name | Emervel classic |
|---|---|
Company | Q-Med, a Galderma Division |
Volume/Package | 1 ml |
Certifications | CE-2010 |
First commercialization | |
Description | Emervel® Classic is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction |
Intended use | Emervel® Classic is an injectable dermal filler used to augment the volume of facial tissues. It is indicated for injection into the mid-dermis for the treatment of moderate to deep wrinkles, or to redefine the shape of the face (cheekbones, tear trough, or lips) |
Duration | Emervel® Classic increases the volume of the dermis for a period of 6–9 months |
Needle | 30 G½ (supplied) |
Trade name | Emervel classic lidocaine |
|---|---|
Company | Q-Med, a Galderma Division |
Volume/Package | 1 ml |
Certifications | CE-2010 |
First commercialization | |
Description | Emervel® Classic lidocaine is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system. 0.3 % lidocaine is added to the formulation to diminish the pain resulting from the injection during the treatment Emervel® Classic lidocaine is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction |
Intended use | Emervel® Classic lidocaine is an injectable dermal filler used to augment the volume of facial tissues. It is indicated for injection into the mid-dermis for the treatment of moderate to deep wrinkles, or to redefine the shape of the face (cheekbones, tear trough, or lips) |
Duration | Emervel® Classic lidocaine increases the volume of the dermis for a period of 6–9 months |
Needle UTW | 30 G½ (supplied) |
Trade name | Emervel deep |
|---|---|
Company | Q-Med, a Galderma Division |
Volume/Package | 1 ml |
Certifications | CE-2010 |
First commercialization | 2011 |
Description | Emervel® Deep is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system |
Emerve® Deep is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction | |
Intended use | Emerve® Deep is an injectable dermal filler used to augment the volume of facial tissues. Emerve®Deep is indicated for injection into the deep dermis for the correction of moderate to deep wrinkles, or to redefine the shape of the face (cheekbones, tear trough, or lips) |
Duration | Emerve® Deep increases the volume of the dermis in a durable manner, for a period of 6–9 months |
Needle UTW | 27 G½ (supplied) |
Cost |
Trade name | Emervel deep lidocaine |
|---|---|
Company | Q-Med, a Galderma Division |
Volume/Package | 1 ml |
Certifications | CE-2010 |
First commercialization | 2011 |
Description | Emerve® Deep lidocaine is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system. 0.3 % lidocaine is added to the formulation to diminish the pain resulting from the injection during the treatment Emerve® Deep lidocaine is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction |
Intended use | Emerve® Deep lidocaine is an injectable dermal filler used to augment the volume of facial tissues. Emervel® Deep lidocaine is indicated for injection into the deep dermis for the correction of moderate to deep wrinkles, or to redefine the shape of the face (cheekbones, tear trough, or lips) |
Duration | Emerve® Deep lidocaine increases the volume of the dermis in a durable manner, for a period of 6–9 months |
Needle UTW | 27 G½ (supplied) |
Trade name | Emervel volume |
|---|---|
Company | Q-Med, a Galderma Division |
Volume/Package | 2 ml |
Certifications | CE-2010 |
First commercialization | 2011 |
Description | Emerve® Volume is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system Emerve® Volume increases the volume of the tissues. Emervel® Volume is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction |
Intended use | Emerve® Volume is an injectable dermal filler used to augment the volume of facial tissues. Emervel® Volume is indicated for injection into the supraperiostic zone or subcutaneous fat tissue for the correction of facial volume (cheeks and chin) |
Duration | Not provided in IFU |
Needle UTW | 23 1 UTW (supplied) |
Cost |
Trade name | Emervel volume lidocaine |
|---|---|
Company | Q-Med, a Galderma Division |
Volume/Package | 2 ml |
Certifications | CE-2010 |
First commercialization | 2011 |
Description | Emerve® Volume is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system. 0.3 % lidocaine is added to the formulation to diminish the pain resulting from the injection during the treatment Emerve® Volume increases the volume of the tissues. Emervel® Volume is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction |
Intended use | Emerve® Volume is an injectable dermal filler used to augment the volume of facial tissues. Emervel® Volume is indicated for injection into the supraperiostic zone or subcutaneous fat tissue for the correction of facial volume (cheeks, chin) |
Duration | Not provided in IFU |
Needle UTW | 23 1 UTW (supplied) |
Trade name | Emervel lips |
|---|---|
Company | Q-Med, a Galderma Division |
Volume/Package | 1 ml |
Certifications | CE-2010 |
First commercialization | 2011 |
Description | Emerve® Lips is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system Emerve® Lips is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction |
Intended use | Emerve® Lips is an injectable dermal filler used to restore and/or augment the volume of the lips |
Duration | Emerve® Lips increases the volume of the dermis for a period of 6–9 months |
Needle | 27 G½ (supplied) |
Trade name | Emervel lips lidocaine |
|---|---|
Company | Q-Med, a Galderma Division |
Volume/Package | 1 ml |
Certifications | CE-2010 |
First commercialization | 2011 |
Description | Emerve® Lips lidocaine is a particulate, monophasic, isotonic, sterile, pyrogen-free, bioresorbable transparent gel consisting of non-animal cross-linked hyaluronic acid (20 mg/ml) in a physiological buffer system. 0.3 % lidocaine is added to the formulation to diminish the pain resulting from the injection during the treatment Emerve® Lips lidocaine is cross-linked with BDDE which regulates resorption of the product, providing lasting volume correction |
Intended use | Emerve® Lips lidocaine is an injectable dermal filler used to restore and/or augment the volume of the lips |
Duration | Emerve® Lips lidocaine increases the volume of the dermis for a period of 6–9 months |
Needle UTW | 27 G½ (supplied) |
Emervel: Reference
1.
Ascher B, Bayerl C, Brun P, Kestemont P, Rzany B, Poncet M, Guennoun M, Podda M (2011) Efficacy and safety of a new hyaluronic acid dermal filler in the treatment of severe nasolabial lines—6 month interim results of a randomized, evaluator-blinded, intra-individual comparison study. J Cosmet Dermatol 10(2):94–98
2.
Rzany B (2012) Emervel®: full-face rejuvenation with a range of customized hyaluronic acid fillers. J Drugs Dermatol 11(1 Suppl):S4
3.
Rzany B, Bayerl C, Bodokh I, Boineau D, Dirschka T, Queille-Roussel C, Sebastian M, Sommer B, Poncet M, Guennoun M, Podda M (2011) Efficacy and safety of a new hyaluronic acid dermal filler in the treatment of moderate nasolabial folds: 6 month interim results of a randomized, evaluator-blinded, intra-individual comparison study. J Cosmet Laser Ther 13(3):107–112
24.5 Glytone Range
24.5.1 Glytone 1 Filler
Trade name | Glytone 1 |
|---|---|
Company | Merz Pharma |
Volume/Package | HA concentration: 14 mg/ml in 2 2 × 1 ml syringes |
Certifications | CE, FDA technology |
First commercialization | 2009 (P. Fabre) 2012 (Europe, Merz Pharma) |
Aree di vendita | France, Italy, Netherlands, Belgium, Luxembourg, Spain and Portugal |
Description | Glytone Professional 1 is a sterile non-pyrogenic physiological gel made of non-reticulated high molecular weight hyaluronic acid of non-animal origin. This gel comes in a pre-filled graduated single-use syringe In combination with HA, there are mannitol known as free radical scavenger for a longer duration and stability and glycerol known for its ability to hydrate in a patented-specific product composition |
Intended use | Glytone Professional 1 is an injectable implant for the mesotherapy to rehydrate deep layers of the skin through repeated injections into dermo-epidermal junction and superficial dermis Glytone Professional 1 can be injected on face, neck, cleavage and hands |
Duration | No published data |
Needle TWN | 4 × 30 G½ (supplied) |
Suggested cannulas | 30 G; 27 G (not supplied) |
Cost |
24.5.2 Glytone 2 Filler
Trade name | Glytone 2 |
|---|---|
Company | Merz Pharma |
Volume/Package | HA concentration: 20 mg/ml in 2 1-ml syringe |
Certifications | CE, FDA technology |
First commercialization in Italy | 2009 (P. Fabre) |
2012 (Merz Pharma) | |
Aree di vendita | France, Italy, Netherlands, Belgium, Luxembourg, Spain and Portugal |
Description | Glytone Professional 2 is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (cross-linking agent: BDDE) of non-animal origin. This gel Glytone 2 is a monophasic filler, and in combination with the cross-linked HA, it contains mannitol known as free radical scavenger for a longer duration and stability and non-cross-linked HA known for its inhibition of matrix-metallo-proteinase which degrades collagen in a patented-specific product composition |
Intended use | Glytone Professional 2 filling superficial wrinkles by injection into the superficial and/or mid-dermis injected on face, neck, cleavage and hands |
Duration | No published data |
Needle TWN | 1 × 27 G½; 1 × 30 G ½ (supplied) |
Suggested cannulas | 30 G; 27 G (not supplied) |
Cost |
24.5.3 Glytone 3 Filler
Trade name | Glytone 3 |
|---|---|
Company | Merz Pharma |
Volume/Package | HA concentration: 23 mg/ml in 2 1-ml syringe |
Certifications | CE, FDA technology |
First commercialization | 2009 (P. Fabre) 2012 (Merz Pharma, Europe) |
Aree di vendita | France, Italy, Netherlands, Belgium, Luxembourg, Spain and Portugal |
Description | Glytone Professional 3 is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (cross-linking agent: BDDE) of non-animal origin. This gel Glytone 3 is a monophasic filler, and in combination with the cross-linked HA, it contains mannitol known as free radical scavenger for a longer duration and stability and non-cross-linked HA known for its inhibition of matrix-metalloproteinase which degrades collagen in a patented-specific product composition |
Intended use | Glytone Professional 3 is an injectable implant for filling deep wrinkles by injection into the mid- and/or deep dermis and to increase lip volume |
Duration | No published data |
Needle TWN | 2 × 27 G ½; (supplied) |
Suggested cannulas | 27 G (not supplied) |
Cost |
24.5.4 Glytone 4 Filler
Trade name | Glytone 4 |
|---|---|
Company | Merz Pharma |
Volume/Package | HA concentration: 24 mg/ml in 2 2x 1 ml syringe |
Certifications | CE, FDA technology |
First commercialization in Italy | 2009 (P. Fabre) 2012 (Merz Pharma) |
Aree di vendita | France, Italy, Netherlands, Belgium, Luxembourg, Spain and Portugal |
Description | Glytone Professional 4 is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (cross-linking agent: BDDE) of non-animal origin. This gel Glytone 4 is a monophasic filler, and in combination with the cross-linked HA, it contains mannitol known as free radical scavenger for a longer duration and stability and non-cross-linked HA known for its inhibition of matrix-metalloproteinase which degrades collagen in a patented-specific product composition |
Intended use | Glytone Professional 4 is an injectable implant for filling deep skin folds, cutaneous depressions, facial localized volume loss by mid-dermal and/or deep dermis injection and for increasing the lips volume |
Duration | No published data |
Needle TWN | 2 × 23 G ¼; 2 × 25 G 5/8 (supplied) |
Suggested cannulas | 25 G (not supplied) |
Cost |
Glytone Range: Reference
1.
Virginie T et al. (2010) Assessment of the clinical efficacy of a hyaluronic acid-based deep wrinkle filler using new instrumental methods. J Cosmetic Therapy 12:195–202
24.6 Hyacorp Range
24.6.1 Hyacorp Filler
Trade name | Hyacorp H 1000 |
|---|---|
Company | Bioscience GmbH |
Volume/Package | 10, 2 ml |
Certifications | CE |
First commercialization | 2009 |
Aree di vendita | All European countries, Japan and Middle East |
Description | Hyacorp is a clear and viscous gel supplied in a special syringe of 10 ml/2 ml. The product is for single use only. The gel consists in a form of a cross-linked hyaluronic acid non-animal source. The particle size is approx. 1,000 μ |
Intended use | Restoration and contouring of body surfaces The depth of the injection may vary from subcutaneous to supraperiostal administration depending on the treatment site |
• Buttocks | |
• Calves | |
• Correction of concave deformities | |
• Regio zygomatica | |
Duration | The degree and duration of the correction depend on the character of the defect treated, the tissue stress at the implant site, the depth of the implant into the tissue and the injection technique |
Needle TWN | Not supplied |
Suggested cannulas | Not supplied |
Trade name | HYACORP H/S 500 |
|---|---|
Company | Bioscience GmbH |
Volume/Package | 10, 2 ml |
Certifications | CE |
First commercialization in Italy | 2010 |
Aree di vendita | All European countries, Japan and Middle East |
Description | Hyacorp is a clear and viscous gel supplied in a special syringe of 10 ml/2 ml. The product is for single use only. The gel consists in a form of a cross-linked hyaluronic acid non-animal source. The particle size is approx. 500 μ |
Intended use | Restoration and contouring of body surfaces The depth of the injection may vary from subcutaneous to supraperiostal administration depending on the treatment site |
• Buttocks | |
• Calves | |
• Correction of concave deformities | |
• Regio zygomatica | |
Duration | The degree and duration of the correction depend on the character of the defect treated, the tissue stress at the implant site, the depth of the implant into the tissue and the injection technique |
Needle TWN | Not supplied |
Suggested cannulas | Not supplied |
Trade name | Hyacorp L |
|---|---|
Company | Bioscience GmbH |
Volume/Package | 2 ml |
Certifications | CE |
First commercialization in Italy | 2009 |
Aree di vendita | Italy, all European countries, Japan and Middle East |
Description | Hyacorp is a clear and viscous gel supplied in a special syringe of 2 ml. The product is for single use only. The gel consists of cross-linked hyaluronic acid non-animal source. The particle size is approx. 350 μ |
Intended use | Restoration of the volume and contour of the body surfaces and the face. The depth of the injection may vary from subcutaneous to supraperiostal administration depending on the treatment site |
Duration | The duration of the filling effect can vary and is depending of the depth and area of injection |
Needle TWN | 22 G × 1 1/4 |
Suggested cannulas | Not supplied |
Trade name | Hyacorp face |
|---|---|
Company | Bioscience GmbH |
Volume/Package | 1 ml |
Certifications | CE |
First commercialization in Italy | 2009 |
Aree di vendita | All European countries, Japan and Middle East |
Description | Hyacorp Face is a clear and viscous gel supplied in a syringe of 1 ml. The product is for single use only. The gel consists of cross-linked hyaluronic acid non-animal source. Particle size approx. 150 μ |
Intended use | Hyacorp Face is designed to be used for the restoration of the facial volume and contour. The gel is injected intradermal and lifts the tissue in a natural way. Warning: Hyacorp Face is only intended for intradermal administration. Do not inject intravascularly |
Duration | The duration of the filling effect can vary and is depending of the depth and area of injection |
Needle TWN | 27 G × 12 mm |
Suggested cannulas | Not supplied |
Trade name | Hyacorp lips |
|---|---|
Company | Bioscience GmbH |
Volume/Package | 1 ml |
Certifications | CE |
First commercialization in Italy | 2009 |
Aree di vendita | All European countries, Japan and Middle East |
Description | Hyacorp Lips is a clear and viscous gel supplied in a syringe of 1 ml. The product is for single use only. The gel consists of cross-linked hyaluronic acid non-animal source. Particle size approx. 150 μ |
Intended use | Hyacorp Lips is designed to be used for the restoration of volume and contouring of the Lips. The gel is injected intradermal and lifts the tissue in a natural way. Warning: Hyacorp Lips is only intended for intradermal administration. Do not inject intravascularly |
Duration | The duration of the filling effect can vary and is depending of the depth and area of injection |
Suggested Needle | 30 G Nano needle |
Suggested cannulas | Not supplied |
Trade name | Hyacorp fine |
|---|---|
Company | Bioscience GmbH |
Volume/Package | 1 ml |
Certifications | CE |
First commercialization in Italy | 2012 |
Aree di vendita | All European countries, Japan and Middle East |
Description | Hyacorp Fine is a sterile, apyrogenic, visco-elastic, biologically compatible (non-immunizing, non-inflammatory, non-toxic) gel implant that is insoluble in water and produced from a hyaluronic acid gained through fermentation |
Intended use | Hyacorp Fine is implanted into the medium dermal tissue to supplement the intercellular matrix and the intradermal tissue and to restore lost anatomical structures of the skin. Its mechanism of action is based on the latest biotechnology in the production of highly purified hyaluronic acid |
Duration | The duration of the filling effect can vary and is depending of the depth and area of injection |
Suggested Needle | 34 G Nano needle |
Suggested cannulas | Not supplied |
Trade name | Ephyal |
|---|---|
Company | Bioscience GmbH |
Volume/Package | 50 ml |
Certifications | CE |
First commercialization in Italy | 2012 |
Aree di vendita | Italy, Russia and Ukraine |
Description | Ephyal Solution is a sterile medical device, certified by the notified body DQS in Frankfurt/Germany with the CE mark 0297. It contains hyaluronic acid non-animal source with a special designed molecular weight |
Intended use | Ephyal is indicated for areas with thin and dry skin. Regions to treat are neck, face, décolleté and hands |
Duration | No published data. Supposed to be up to 6 months |
Suggested Needle | Not supplied |
24.7 Juvéderm® Hydrate™
Trade name | Juvéderm ® Hydrate™ |
|---|---|
Company | ALLERGAN |
Certification |
